For this purpose, the PIK3CA specific inhibitor, PIK75 [27], and the disruptor of Yap-TEAD interaction, Verteporfin [28], were applied either alone or in combination in HLF and SK/Hep1 HCC cell lines and the EGI1 CCA cell line (Figure 8A and B, Supplementary Figure 5). The gene discussed is PIK3CA; the disease is hepatocellular carcinoma.